Maa: Yhdysvallat
Kieli: englanti
Lähde: NLM (National Library of Medicine)
Sucralfate (UNII: XX73205DH5) (Sucralfate - UNII:XX73205DH5)
Precision Dose, Inc.
ORAL
PRESCRIPTION DRUG
Sucralfate Oral Suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. Sucralfate Oral Suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.
Sucralfate Oral Suspension 1 g/10 mL is a pink suspension NDC 68094-043-61 10 mL per unit dose cup One hundred (100) cups per shipper NDC 68094-043-62 10 mL per unit dose cup Thirty (30) cups per shipper SHAKE WELL BEFORE USING. AVOID FREEZING. Store at Controlled Room Temperature 20-25° C (68-77° F) [see USP]
New Drug Application Authorized Generic
SUCRALFATE- SUCRALFATE SUSPENSION PRECISION DOSE, INC. ---------- SUCRALFATE ORAL SUSPENSION 1G/10ML RX ONLY DESCRIPTION Sucralfate Oral Suspension contains sucralfate and sucralfate is an α-D- glucopyranoside, β-D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. [Al(OH) ] x [H O]y (x=8 to 10 and y= 22 to 31) R= SO Al(OH) Sucralfate Oral Suspension for oral administration contains 1g of sucralfate per 10 mL. Sucralfate Oral Suspension also contains: colloidal silicon dioxide NF, FD&C Red #40, flavor, glycerin USP, methylcellulose USP, methylparaben NF, microcrystalline cellulose NF, purified water USP, simethicone USP, and sorbitol solution USP. Therapeutic category: antiulcer. CLINICAL PHARMACOLOGY Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine. Although the mechanism of sucralfate's ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action. The following observations also appear pertinent: 1. Studies in human subjects and with animal models of ulcer disease have shown that sucralfate forms an ulcer-adherent complex with proteinaceous exudate at the ulcer site. 2. In vitro, a sucralfate-albumin film provides a barrier to diffusion of hydrogen ions. 3. In human subjects, sucralfate given in doses recommended for ulcer therapy inhibits pepsin activity in gastric juice by 32%. In vitro, sucralfate adsorbs bile salts. These observations suggest that sucralfate's antiulcer activity is the result of formation of an ulceradherent complex that covers the ulcer site and protects it against further attack by acid, pepsin, and bile salts. There are approximately 14 to 16 mEq of acid- neutralizing capacity per 1-g dose of sucralfate. 3 2 3 2 CLINICAL TRIALS In a multicenter, double-blind, placebo-controlled study of Sucralfate Oral Suspension, a dosage regimen of 1 gram (10 mL) four Lue koko asiakirja